Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,419 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Active capsule Clear all

Conditions: Obsessive-Compulsive Disorder
Interventions: ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 25 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Palo Alto, California • Boston, Massachusetts

Conditions: Erosive Esophagitis
Interventions: X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy; Drug
Lead sponsor: Cinclus Pharma Holding AB; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more

Conditions: Ulcerative Colitis
Interventions: PTG-100, Placebo; Drug
Lead sponsor: Protagonist Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Los Angeles, California • Colorado Springs, Colorado • Miami, Florida + 17 more

Conditions: Secondary Hypogonadism
Interventions: 25 mg Androxal, Testim 1%; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 21 Years to 60 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: New York, New York • Purchase, New York

Conditions: Non-small Cell Lung Cancer
Interventions: H002; Drug
Lead sponsor: RedCloud Bio; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Bipolar Disorder, Bipolar Depression
Interventions: N-acetylcysteine, Minocycline, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overactive Bladder
Interventions: onaBoNT-A, Oxybutynin ER; Drug
Lead sponsor: Christopher Patrick Smith; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Cervical Dysplasia
Interventions: di indolylmethane (DIM), Red rice bran; Drug · Dietary Supplement
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression
Interventions: Deep Brain Stimulation System; Device
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 4 Years to 5 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: South Miami, Florida • Durham, North Carolina

Conditions: Neutrophil Chemotactic Response
Interventions: Exercise, ProLab 200mg caffeine capsule, Ethanol ingestion, Glucose Tolerance Drink; Behavioral · Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: HQK-1001, placebo; Drug
Lead sponsor: HemaQuest Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Parkinson's Disease, Cognitive Impairment
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 35 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cognitive Decline
Interventions: vitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, Fish oil placebo; Dietary Supplement · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years to 92 Years
Enrollment: 3,424 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Suicidal Ideation
Interventions: Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Systemic Lupus Erythematosus
Interventions: GLPG3667, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Tucson, Arizona • La Jolla, California • Rancho Mirage, California + 16 more

Conditions: Known Crohn Disease Subjects
Interventions: Capsule endoscopy and Ileocolonoscopy tests; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 12 more

Conditions: Chronic Pancreatitis
Interventions: Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Rochester, Minnesota • Columbus, Ohio

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Rochester, Minnesota • Durham, North Carolina

Conditions: Cocaine Dependence
Interventions: Adderall-ER, Topiramate, Placebo; Drug · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more

Conditions: Chronic Low Back Pain
Interventions: Lidoderm®, Celecoxib; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 21
States / cities: Northport, Alabama • Phoenix, Arizona • Beverly Hills, California + 18 more

Conditions: Prostate Cancer
Interventions: Vitamin D, Omega-3, Turmeric; Dietary Supplement
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Sonication-based OCD Neurosurgical Intervention Via Capsulotomy

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

Electrical Stimulation of the Internal Capsule for Intractable Depression

Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

Influence of Lifestyle Factors on Neutrophil Migration Pilot Study

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects

Trial of Indomethacin in Chronic Pancreatitis

Statins for the Treatment of NASH

Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence

A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain

Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer